Traduction de «Médicament contre le VIH » (Français → Anglais) :

More than 30 projects on HIV/AIDS vaccines and drugs are currently being funded, both in Europe, Africa, Asia and South-America.

As this Regulation is part of wider action to address the issue of access to affordable medicines for developing countries, complementary actions are set out in the Commission Programme for Action: Accelerated action on HIV/AIDS, malaria and tuberculosis in the context of poverty reduction and in the Commission Communication on a Coherent European Policy Framework for External Action to Confront HIV/AIDS, malaria and tuberculosis.

Projects include development of: (i) new anti-retroviral treatments to overcome growing resistance of the virus; (ii) new interventions for the treatment of HIV-infected infants, pregnant women and adults; (iii) HIV microbicides to allow women that do not have the capacity to impose HIV prevention measures (safer sex through condom use) on their partners to protect themselves against HIV transmission; (iv) new and promising HIV vaccine candidates not only to prevent the HIV infection, but also to treat infected people; (v) new anti-HIV drugs against hidden virus that can not be accessed by other drugs, and against the escape of the virus from infect ...[+++]ed cells, (vi) vaccine delivery systems to fight viruses; and (vi) specific support actions for standardising clinical tests and monitoring HIV resistance.

Research projects are now coming on stream particularly concerning: Prevention of mother to child transmission of HIV/AIDS; increasing effectiveness of anti-retroviral drugs; identifying markers of anti-Tuberculosis drug efficacy; phase II-III of tuberculosis and malaria drug trials, and capacity building for HIV/AIDS vaccine and microbicide trials (a female controlled HIV prevention technology).

A distinction must be made between drugs that don't result in any improvement and medications that can prolong the lives of people living with HIV. Given the nature of viral resistance to HIV medications, and that the cost of changing an ineffective drug for a functional one is negligible, people living with HIV need quick access to new and different treatment options.

On 21 February 2001, the Commission adopted a communication to the European Parliament and to the Council on accelerated action targeted at major communicable diseases within the context of poverty reduction, according to which the Commission was instructed, inter alia, to establish a global tiered pricing system for key pharmaceuticals for the prevention, diagnosis and treatment of HIV/AIDS, TB and malaria and related diseases for the poorest developing countries and to prevent product diversion of these products to other markets by ...[+++]ensuring that effective safeguards were in place.